Clinical Study Data Request Registered Users, Please Login

Scroll down the list of studies provided below. Studies are listed by study medicine in alphabetical order. Alternatively you can browse the list of studies using the search function.

To select studies and submit a research proposal or enquiry, go back to the Home page and select View and submit.

This takes you back to the previous page to enable you to view studies from a different sponsor.

Select medicine, medical condition or phase from the drop down boxes. This searches all the available clinical studies. Selecting from more than one drop down box will “and” the criteria.

Find by:


Alternatively search for studies using the Takeda Clinical Study Identification Number or study title by entering text and clicking search.

 

356 found

Click the study title to find more information about the study.

TAKEDA-SYR-322-OLE-012
A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects With Type 2 Diabetes

Medicine: alogliptin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: SYR-322-OLE-012, Sponsor: Takeda
TAKEDA-SYR-322-PLC-010
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) Compared With Placebo in Subjects With Type 2 Diabetes

Medicine: alogliptin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: SYR-322-PLC-010, Sponsor: Takeda
TAKEDA-SYR-322-SULF-007
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With a Sulfonylurea in Subjects With Type 2 Diabetes

Medicine: alogliptin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: SYR-322-SULF-007, Sponsor: Takeda
TAKEDA-SYR-322-TZD-009
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Pioglitazone in Subjects With Diabetes Mellitus, Type 2

Medicine: alogliptin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: SYR-322-TZD-009, Sponsor: Takeda
*TAKEDA-SYR-322/CCT-001
A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 in Subjects With Type 2 Diabetes in Japan

Medicine: alogliptin, Condition: Diabetes Mellitus, Type 2, Phase: 2, Clinical Study ID: SYR-322/CCT-001, Sponsor: Takeda
TAKEDA-SYR-322/CCT-003
A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With a-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan

Medicine: alogliptin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: SYR-322/CCT-003, Sponsor: Takeda
TAKEDA-SYR-322/CCT-004
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan

Medicine: alogliptin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: SYR-322/CCT-004, Sponsor: Takeda
TAKEDA-SYR-322/CCT-005
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Sulfonylurea in Subjects With Type 2 Diabetes in Japan

Medicine: alogliptin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: SYR-322/CCT-005, Sponsor: Takeda
TAKEDA-SYR-322/CCT-006
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Metformin in Subjects With Type 2 Diabetes in Japan

Medicine: alogliptin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: SYR-322/CCT-006, Sponsor: Takeda
TAKEDA-SYR-322/CCT-901
A Phase 3 Study to Investigate the Efficacy and Safety of SYR-322 When Used in Combination With Insulin Preparation in Subjects With Type 2 Diabetes in Japan

Medicine: alogliptin, Condition: Diabetes Mellitus, Type 2, Phase: 3, Clinical Study ID: SYR-322/CCT-901, Sponsor: Takeda
First Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  ... Next Last